Tumor Profiling as an Important Diagnostic Tool

Cancer of unknown primary comprises a heterogeneous group of patients with metastatic cancer. They are ideal candidates for the classification of their tissue of origin by gene expression profiling of their biopsies. Tumor profiling is a potentially powerful tool for gene expression profiling to identify the tissue of origin in patients with cancer of unknown primary.

Several studies have shown that molecular profiling of cancer cells is useful in the diagnosis of the tissue of origin, which has been reported to improve the survival of patients with cancer of unknown primary, by allowing more site-specific therapy rather than the empiric regimens. As therapies for solid tumors improve, the value of an accurate diagnosis of the tissue of origin becomes increasingly important. Tumor profiling assays have been shown as a group to be >85% accurate in determining the cancer type of known metastatic and primary cancers.

Tumor Profiling at Creative Biolabs

Based on next-generation sequencing (NGS) technology, Creative Biolabs provides a comprehensive and efficient method for assessing the majority of genes associated with solid tumors, including lung, colon, breast tumor profiling, melanoma, pancreatic, brain tumor profiling, ovarian, endometrial, thyroid, head and neck cancer (HNC).

Comprehensive tumor profiling based on NGS methods can be used to:

• To detect targetable mutations in otherwise difficult-to-treat, chemoresistant or metastatic tumors
• To provide targetable options for tumors that could not be histologically adequately classified
• To determine the origin of a metastatic tumor of unknown primary
• To provide a refined diagnosis in cases of undifferentiated malignancies
• To detect circulating genetic material or tumor cells in liquid biopsies from patients with metastatic disease

Workflow of NGS-based Tumor Profiling

Advantages of NGS-based Tumor Profiling at Creative Biolabs

• Simple workflow
• Using a single sequencing instrument
• Selecting a set of genes, gene regions, or amplicons based on known involvement with solid tumors
• Detecting rare mutations and tumor subclones with high sensitivity
• Identifying cancer’s unique hallmarks
• Diagnosis in unknown primary cancer:

The development and applications of tumor profiling methods will be the key to offering novel methods of cancer treatment. Comprehensive cancer profiling offers an alternative approach for the research of treating patients with difficult cancers. Tumor profiling is conducive to the development of accurate and less expensive molecular diagnostic tests that accurately predict the response to targeted therapy. Creative Biolabs is committed to providing overall solutions in this field. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Greco, F.A.; et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. JNCI: Journal of the National Cancer Institute. 2013, 105(11): 782-90.

For Research Use Only | Not For Clinical Use